BAY88-8223, Does Response Study in HRPC Patients

Inclusion criteria: * Histologically/cytologically confirmed adenocarcinoma of the prostate * Patient is hormone refractory with evidence of progressive disease: * Patient must be maintained on androgen ablation therapy with LHRH agonist or have undergone orchiectomy * Patient's testosterone level is required to be equal to or below 50 ng/dl * Patients in which flutamide, nilutamide, megestrol acetate, polyestradiol phosphate, aminoglutethimide, and ketoconazole, has been recently withdrawn must demonstrate progression of disease and be at last 4 weeks beyond the discontinuation of such agents; for bicalutamide 6 weeks is required * Increase in PSA levels in two consecutive measurements with at least one week apart, demonstrating an increase over the reference (nadir) value, and with the final PSA \>/= 5 ng/ml * A reference PSA (nadir) value must be measured at least 4 weeks after the discontinuation of flutamide, nilutamide, megestrol acetate, polyestradiol phosphate, aminoglutethimide, and ketoconazole, and at least 6 weeks after discontinuation of bicalutamide * If the third PSA value is lower than the second value, the patient could still be eligible, provided a fourth measurement obtained at least 1 week after the third PSA value, is grater than the second PSA value and \>/= 5 ng/ml * Multifocal (\>1) skeletal metastases confirmed by bone scintigraphy within 6 weeks * Bone pain with a score of at least 2 on BPI average pain, despite adequate use of ana…